Antibody Therapeutics · 2024 · 21 citations · 49 references
PharmacyOncologyPharmaceuticsAntibody EngineeringDrug DeliveryMonoclonal AntibodiesAntibody ConjugatesAntibody ConjugationAntibody DiscoveryAntibody Fragment EngineeringAntibody-drug ConjugatesTherapeutic Monoclonal AntibodiesAntibody Format DesignAntibody Format EngineeringAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyAntibody-enzyme ConjugatesConjugation Of Antibody FragmentsTumor PenetrationTumor Penetration Of Drugs
In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires surmounting extant challenges, mainly the limitations in tumor penetration capabilities when targeting solid tumors. To resolve the hurdle of suboptimal tumor penetration, miniaturized antibody fragments with engineered formats have been harnessed for ADC assembly. By virtue of their reduced molecular sizes, antibody fragment-drug conjugates hold considerable promise for efficacious delivery of cytotoxic agents, thus conferring superior therapeutic outcomes. This review will focus on current advancements in novel ADC development utilizing smaller antibody formats from ~6 to 80 kDa, with particular emphasis on single-domain antibodies, which have been widely applied in novel ADC design. Additionally, strategies to optimize clinical translation are discussed, including half-life extension, acceleration of internalization, and reduction of immunogenic potential.
49
Biophysical Properties of Human Antibody Variable Domains
Stefan Ewert, Thomas Huber, Annemarie Honegger et al. · Journal of Molecular Biology · 2002 · 330 citations
Identification of Human Single-Domain Antibodies against SARS-CoV-2
Yanling Wu, Cheng Li, Shuai Xia et al. · Cell Host & Microbe · 2020 · 281 citations · Full text